Updates and news related to prostate cancer:
New prostate cancer target could reactivate standard of care treatments.
The treatment landscape for metastatic, hormone-sensitive prostate cancer has transformed in recent years, with the emphasis now on early treatment intensification through a combination approach to systemic therapy.
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Senior author Kevin Ginsburg, MD, said he and his coauthors observed wide variation by practice in the use of active surveillance in this patient population.
Radiotherapy to the prostate alongside standard treatment can keep some men with advanced prostate cancer alive for longer without detriment to quality of life, long-term study results confirm.
Research shows a possible connection.
This article serves as a summary of the literature published in the past 3 years, documenting the impact of exercise and physical activity on prostate cancer development and on cancer-specific, treatment-related, and patient-reported outcomes.
Abiraterone acetate, used together with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body, now available at significant savings.
Research shows a promising new option for men who experience rising PSA after a radical prostatectomy.
Focal therapy using MRI-guided focused ultrasound is safe and effective for men with intermediate-risk prostate cancer who seek to avoid more invasive treatments, according to a study.